Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 13 | 2020 | 116 | 2.710 |
Why?
|
| Sarcoma | 10 | 2021 | 71 | 2.190 |
Why?
|
| Soft Tissue Neoplasms | 8 | 2021 | 40 | 1.940 |
Why?
|
| Chondrosarcoma | 5 | 2020 | 8 | 1.130 |
Why?
|
| Brachytherapy | 2 | 2018 | 24 | 0.920 |
Why?
|
| Extremities | 4 | 2021 | 54 | 0.690 |
Why?
|
| Orthopedics | 2 | 2019 | 94 | 0.670 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2021 | 384 | 0.630 |
Why?
|
| Spinal Neoplasms | 1 | 2019 | 22 | 0.600 |
Why?
|
| Spine | 1 | 2019 | 44 | 0.600 |
Why?
|
| Incidental Findings | 1 | 2019 | 26 | 0.590 |
Why?
|
| Joint Instability | 2 | 2019 | 86 | 0.580 |
Why?
|
| Diffusion of Innovation | 1 | 2018 | 34 | 0.570 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 57 | 0.560 |
Why?
|
| Internship and Residency | 2 | 2019 | 324 | 0.550 |
Why?
|
| Radiation Dosage | 1 | 2018 | 84 | 0.550 |
Why?
|
| Humerus | 2 | 2013 | 31 | 0.540 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 133 | 0.510 |
Why?
|
| Lipoma | 1 | 2015 | 7 | 0.460 |
Why?
|
| Humans | 33 | 2021 | 32798 | 0.460 |
Why?
|
| Retrospective Studies | 14 | 2025 | 3701 | 0.450 |
Why?
|
| Tendon Injuries | 1 | 2014 | 40 | 0.430 |
Why?
|
| Middle Aged | 19 | 2020 | 12125 | 0.410 |
Why?
|
| Osteochondroma | 1 | 2013 | 3 | 0.400 |
Why?
|
| Giant Cell Tumors | 1 | 2013 | 4 | 0.400 |
Why?
|
| Limb Salvage | 7 | 2021 | 24 | 0.400 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2020 | 1307 | 0.390 |
Why?
|
| Tendons | 1 | 2013 | 59 | 0.390 |
Why?
|
| Adult | 17 | 2020 | 9560 | 0.390 |
Why?
|
| Wrist Joint | 1 | 2013 | 60 | 0.390 |
Why?
|
| Cell Proliferation | 2 | 2020 | 602 | 0.370 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2020 | 14 | 0.330 |
Why?
|
| Female | 21 | 2025 | 20261 | 0.330 |
Why?
|
| Aged | 15 | 2019 | 10538 | 0.320 |
Why?
|
| Male | 18 | 2025 | 19641 | 0.320 |
Why?
|
| Radiography | 4 | 2016 | 386 | 0.320 |
Why?
|
| Neoplastic Stem Cells | 2 | 2020 | 98 | 0.310 |
Why?
|
| Bone Transplantation | 3 | 2019 | 51 | 0.300 |
Why?
|
| Young Adult | 9 | 2020 | 2730 | 0.290 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 563 | 0.280 |
Why?
|
| Cerebral Arteries | 1 | 2008 | 19 | 0.280 |
Why?
|
| Adolescent | 9 | 2019 | 3638 | 0.280 |
Why?
|
| Postoperative Complications | 3 | 2025 | 828 | 0.280 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2008 | 74 | 0.270 |
Why?
|
| Cerebrovascular Circulation | 1 | 2008 | 95 | 0.260 |
Why?
|
| Brain Ischemia | 1 | 2008 | 147 | 0.250 |
Why?
|
| Femoral Neoplasms | 2 | 2010 | 4 | 0.240 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 887 | 0.230 |
Why?
|
| Neoplasm, Residual | 4 | 2016 | 25 | 0.230 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 4032 | 0.230 |
Why?
|
| Physical Examination | 3 | 2013 | 89 | 0.230 |
Why?
|
| Dog Diseases | 1 | 2025 | 12 | 0.220 |
Why?
|
| Hypocalcemia | 1 | 2025 | 14 | 0.220 |
Why?
|
| Parathyroidectomy | 1 | 2025 | 22 | 0.220 |
Why?
|
| Fibrous Dysplasia of Bone | 2 | 2014 | 2 | 0.220 |
Why?
|
| Treatment Outcome | 7 | 2018 | 3438 | 0.220 |
Why?
|
| Parathyroid Hormone | 1 | 2025 | 47 | 0.220 |
Why?
|
| Biopsy | 3 | 2013 | 245 | 0.220 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2025 | 17 | 0.220 |
Why?
|
| Curettage | 2 | 2019 | 10 | 0.190 |
Why?
|
| Reoperation | 3 | 2019 | 260 | 0.190 |
Why?
|
| Biopsy, Needle | 2 | 2016 | 90 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2018 | 80 | 0.190 |
Why?
|
| Fractures, Spontaneous | 2 | 2019 | 15 | 0.190 |
Why?
|
| Amyloidosis | 1 | 2021 | 16 | 0.180 |
Why?
|
| Joint Diseases | 1 | 2021 | 36 | 0.180 |
Why?
|
| Orthopedic Procedures | 2 | 2019 | 95 | 0.180 |
Why?
|
| Tibia | 2 | 2014 | 60 | 0.170 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2010 | 5 | 0.170 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 9 | 0.160 |
Why?
|
| Office Visits | 1 | 2010 | 73 | 0.160 |
Why?
|
| Mycetoma | 1 | 2009 | 1 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2010 | 109 | 0.150 |
Why?
|
| Subcutaneous Fat | 1 | 2020 | 49 | 0.150 |
Why?
|
| Leg Dermatoses | 1 | 2009 | 2 | 0.150 |
Why?
|
| Cementation | 1 | 2019 | 2 | 0.150 |
Why?
|
| Foot Diseases | 1 | 2009 | 12 | 0.150 |
Why?
|
| Bone Cements | 1 | 2019 | 11 | 0.150 |
Why?
|
| Ulcer | 1 | 2009 | 3 | 0.150 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2009 | 16 | 0.150 |
Why?
|
| Hydrogen Peroxide | 1 | 2019 | 84 | 0.150 |
Why?
|
| Lower Extremity | 1 | 2020 | 107 | 0.150 |
Why?
|
| Knee Injuries | 1 | 2019 | 40 | 0.150 |
Why?
|
| Palliative Care | 1 | 2019 | 51 | 0.150 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 100 | 0.140 |
Why?
|
| Osteotomy | 1 | 2019 | 57 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2019 | 123 | 0.140 |
Why?
|
| Specialties, Surgical | 1 | 2018 | 28 | 0.140 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2018 | 13 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 157 | 0.140 |
Why?
|
| Athletic Injuries | 1 | 2019 | 93 | 0.130 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2019 | 91 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 98 | 0.130 |
Why?
|
| Wound Healing | 1 | 2018 | 188 | 0.130 |
Why?
|
| Tarsal Bones | 1 | 2016 | 5 | 0.130 |
Why?
|
| Range of Motion, Articular | 2 | 2013 | 195 | 0.130 |
Why?
|
| Pediatrics | 1 | 2018 | 155 | 0.130 |
Why?
|
| Pain | 1 | 2009 | 294 | 0.130 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2016 | 8 | 0.130 |
Why?
|
| Prognosis | 5 | 2015 | 1544 | 0.120 |
Why?
|
| Diagnosis, Differential | 4 | 2014 | 526 | 0.120 |
Why?
|
| Shoulder Joint | 1 | 2008 | 137 | 0.120 |
Why?
|
| Arthrodesis | 1 | 2016 | 31 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2018 | 1460 | 0.110 |
Why?
|
| Time Factors | 2 | 2018 | 2183 | 0.110 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2014 | 7 | 0.110 |
Why?
|
| Osteitis Deformans | 1 | 2014 | 2 | 0.110 |
Why?
|
| Enchondromatosis | 1 | 2014 | 3 | 0.110 |
Why?
|
| Exostoses, Multiple Hereditary | 1 | 2014 | 2 | 0.110 |
Why?
|
| Sutures | 1 | 2014 | 20 | 0.110 |
Why?
|
| Risk Factors | 2 | 2018 | 3974 | 0.100 |
Why?
|
| United States | 2 | 2019 | 4108 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 456 | 0.100 |
Why?
|
| Wound Infection | 1 | 2012 | 12 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2012 | 35 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2013 | 203 | 0.090 |
Why?
|
| Child | 4 | 2010 | 2478 | 0.080 |
Why?
|
| Cell Survival | 2 | 2020 | 280 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 470 | 0.080 |
Why?
|
| Artificial Limbs | 1 | 2008 | 1 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 726 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2008 | 51 | 0.070 |
Why?
|
| Blood Flow Velocity | 1 | 2008 | 77 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 459 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 2284 | 0.060 |
Why?
|
| Dogs | 1 | 2025 | 120 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 205 | 0.050 |
Why?
|
| Femur | 2 | 2014 | 79 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 326 | 0.050 |
Why?
|
| beta 2-Microglobulin | 1 | 2021 | 6 | 0.050 |
Why?
|
| Amyloid | 1 | 2021 | 16 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 23 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2020 | 24 | 0.040 |
Why?
|
| Necrosis | 1 | 2010 | 51 | 0.040 |
Why?
|
| Retinal Dehydrogenase | 1 | 2020 | 2 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2020 | 38 | 0.040 |
Why?
|
| Florida | 1 | 2010 | 38 | 0.040 |
Why?
|
| Chromatin | 1 | 2020 | 26 | 0.040 |
Why?
|
| Itraconazole | 1 | 2009 | 6 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 107 | 0.040 |
Why?
|
| Periosteum | 1 | 2009 | 9 | 0.040 |
Why?
|
| Osteosarcoma | 1 | 2009 | 11 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 947 | 0.040 |
Why?
|
| Toes | 1 | 2009 | 16 | 0.040 |
Why?
|
| Hemangioma | 1 | 2009 | 22 | 0.040 |
Why?
|
| Arthrography | 1 | 2009 | 10 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2009 | 41 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2021 | 280 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 264 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 622 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2008 | 39 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 130 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 151 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2008 | 51 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2008 | 47 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 767 | 0.030 |
Why?
|
| Knee Joint | 1 | 2009 | 143 | 0.030 |
Why?
|
| Comorbidity | 1 | 2009 | 573 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2008 | 486 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2009 | 356 | 0.030 |
Why?
|
| Fracture Fixation, Internal | 1 | 2008 | 124 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 682 | 0.030 |
Why?
|
| Ifosfamide | 1 | 2016 | 6 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2019 | 338 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 99 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2016 | 21 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 764 | 0.030 |
Why?
|
| Cisplatin | 1 | 2016 | 81 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 66 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2016 | 83 | 0.030 |
Why?
|
| Pregnancy | 1 | 2009 | 981 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 167 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 2015 | 49 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 497 | 0.030 |
Why?
|
| Ilium | 1 | 2014 | 16 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2015 | 77 | 0.030 |
Why?
|
| Pelvic Bones | 1 | 2014 | 34 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 894 | 0.030 |
Why?
|
| Ribs | 1 | 2014 | 47 | 0.030 |
Why?
|
| Calcinosis | 1 | 2014 | 146 | 0.030 |
Why?
|
| Animals | 1 | 2025 | 7569 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 60 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 428 | 0.020 |
Why?
|
| Hip Prosthesis | 1 | 2008 | 16 | 0.020 |
Why?
|
| Prosthesis Implantation | 1 | 2008 | 39 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2008 | 220 | 0.020 |
Why?
|
| Walking | 1 | 2008 | 210 | 0.020 |
Why?
|
| Age Factors | 1 | 2008 | 1197 | 0.010 |
Why?
|